跳至主要内容
临床试验/EUCTR2006-005442-37-NL
EUCTR2006-005442-37-NL进行中(未招募)不适用

PITUITARY DAMAGE AFTER TRAUMATIC BRAIN INJURY; Occurrence of growth hormone deficiency at long term follow-up and the beneficial effects of growth hormone substitution on cardiovascular performance, quality of life and functional abilities - Growth hormone substitution in isolated growth hormone deficiency after traumatic brain injury

niversity Medical Center St Radboud, department of neurology0 个研究点开始时间: 2006年11月2日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. The patient visits the emergency department with mild, moderate or severe traumatic brain injury. (Mild traumatic brain injury is defined as a history of impact to the head and a Glasgow Coma Scale score (GCS) 13-15 at entry in the emergency room, moderate traumatic brain injury is defined as a GCS 9-12 at entry in the emergency room, and severe traumatic brain injury is defined as a GCS <= 8 at entry in the emergency room)
  • 2. The trauma has occurred less than 24 hours before visiting the emergency department.
  • 3. Age = 18 years and = 65 years at the time of inclusion
  • 4. Absolute growth hormone deficiency (defined as growth hormone response < 9 mE/l in the GHRH-arginine test), diagnosed within one of the protocols going with ABR form no. 14996 or 14998
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Age > 65 or < 18 years
  • 2. No oral or written informed consent by patient or proxy
  • 3. Pre-existent neuro-endocrine disorder
  • 4. Co-existent dysfunction of pituitary axis other than the somatotropic axis
  • 5. Instable infiltrative disease in the hypothalamus/pituitary region (eg sarcoidosis, tumour metastasis)
  • 6. BMI >30 kg/m2
  • 7. Primary dyslipidemia that necessitates treatment
  • 8. Positive family history of premature cardiovascular disease
  • 9. Overt diabetes mellitus type II (including a history of gestational diabetes mellitus)
  • 10. Impairment in renal function (Creatinin clearance < 60 ml/min)
  • 11. Pregnancy or wish for pregnancy during the study period, lactation
  • 12. Retinal disease
  • 13. Co-existent disease with decreased life expectancy, especially active malignant tumor
  • 14. Chronic alcohol or drug abuse

研究者

发起方
niversity Medical Center St Radboud, department of neurology

相似试验